Impact of Ambulatory Continuous Monitoring Using Remote Monitoring Medicine Within Patient's Care Pathway Following Colorectal Surgery (CONTACT-GRECCAR 21)

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorNantes University Hospital

About this trial

The goal of this Clinical Investigation is to evaluate the effectiveness of implementing the discharge protocol of the remote monitoring platform after colorectal surgery in patients at risk of hospital readmission.

Participants will be randomized into either the "30 days of remote monitoring" group or the "conventional discharge" group. The patient returns to the site for their postoperative visit at 30 days and is contacted by phone 90 days after their surgery.

Eligibility criteria

Qualifiers

Man or woman over 18 years old at the time of the J0 visit,

Patient who underwent surgery less than 28 days ago, or who is scheduled to undergo colorectal surgery not managed as an outpatient procedure at the investigational center, including resection of at least one colonic or rectal segment and/or an anastomosis involving the colon or rectum,

Anticipated early discharge (within 24 hours following laparoscopic surgery without stoma and without diversion, and within 5 days following laparotomy and/or surgery with stoma and/or rectal surgery) for a procedure that is not usually managed as an outpatient surgery in routine practice,

Estimated risk of hospital readmission greater than 10% according to the nomogram of Tevis et al. [15], adapted to the postoperative context in digestive surgery (>120 points according to this score).

Disqualifiers

Discharge to a rehabilitation center requested by the patient,

Condition managed on an outpatient basis in routine practice for this type of patient,

Patient eligible for home hospitalization services,

Suicidal or hetero-aggressive risk in a patient living alone at home

Trial design

Treatments tested in this trial

  • Remote monitoring platform

Treatment groups

362 Participants
are divided into 2 treatment groups

Sponsors and collaborators

Nantes University Hospital

Lead sponsor

EPOCA U&I

Collaborator

Ministry of Health, France

Collaborator